Loading...
XSHG600267
Market cap1.24bUSD
Jan 14, Last price  
7.91CNY
1D
2.46%
1Q
-2.10%
Jan 2017
-39.85%
Name

Zhejiang Hisun Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600267 chart
P/E
—
P/S
0.88
EPS
—
Div Yield, %
2.18%
Shrs. gr., 5y
3.82%
Rev. gr., 5y
0.36%
Revenues
10.37b
-13.82%
1,779,836,1801,905,870,4132,261,985,6062,838,770,7413,181,978,2634,003,470,4374,544,508,9595,161,394,2145,801,766,0628,604,311,58310,096,747,8628,767,428,1409,733,423,46010,571,526,72310,187,440,96511,071,784,24211,354,395,74312,136,465,76512,036,690,08110,373,071,956
Net income
0k
-100.00%
217,246,037115,876,71280,338,876139,672,066195,320,954272,250,101365,761,620504,081,307301,289,979301,857,409307,896,70613,566,704013,566,2260323,265,742723,167,293486,888,358488,860,0510
CFO
1.52b
-26.57%
312,933,919113,527,315108,028,871437,720,980221,276,654472,846,967509,179,184525,312,010375,746,180527,249,352571,038,090736,168,523775,899,3371,240,708,2471,446,308,104698,388,3711,589,608,7561,736,524,2432,065,736,6081,516,960,545
Dividend
May 19, 20230.17 CNY/sh

Profile

Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures and supplies pharmaceutical products in China. It provides active pharmaceutical ingredients and finished dosage form products. The company offers products in the areas of anti-tumor, cardiovascular, anti-infective, liver care, orthopedics, anticancer, anti-parasitic, immunosuppressant, etc.; and weight loss, anti-viral, anti-TB, veterinary pharma, and others. It also provides product consultation and CMO/CRO manufacturing services. The company was founded in 1956 and is headquartered in Taizhou, China.
URL
http://www.hisunpharm.com/
IPO date
Jul 25, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
10,373,072
-13.82%
12,036,690
-0.82%
Cost of revenue
9,114,122
10,099,395
Unusual Expense (Income)
NOPBT
1,258,950
1,937,295
NOPBT Margin
12.14%
16.09%
Operating Taxes
14,148
192,003
Tax Rate
1.12%
9.91%
NOPAT
1,244,802
1,745,292
Net income
488,860
0.40%
Dividends
(199,183)
(166,258)
Dividend yield
1.83%
1.31%
Proceeds from repurchase of equity
(109,231)
BB yield
1.00%
Debt
Debt current
2,167,747
3,038,943
Long-term debt
2,426,728
3,121,877
Deferred revenue
185,963
207,152
Other long-term liabilities
74,080
Net debt
1,593,261
3,173,247
Cash flow
Cash from operating activities
1,516,961
2,065,737
CAPEX
(240,039)
Cash from investing activities
(338,706)
Cash from financing activities
(1,004,207)
FCF
2,512,881
2,594,844
Balance
Cash
1,586,920
1,398,783
Long term investments
1,414,294
1,588,790
Excess cash
2,482,560
2,385,739
Stockholders' equity
3,437,532
4,500,645
Invested Capital
10,692,224
12,057,959
ROIC
10.94%
13.86%
ROCE
9.54%
13.40%
EV
Common stock shares outstanding
1,164,641
1,152,571
Price
9.36
-15.06%
11.02
-21.23%
Market cap
10,901,043
-14.17%
12,701,330
-20.01%
EV
12,741,743
16,125,679
EBITDA
2,303,517
2,977,223
EV/EBITDA
5.53
5.42
Interest
215,402
283,124
Interest/NOPBT
17.11%
14.61%